Skip to main content

Idiopathic Parkinson Disease

Neurology
6
Pipeline Programs
10
Companies
10
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
2
1
0
0
1
Early DiscoveryClinical DevelopmentMarket

Neurology is a $26.9B market dominated by a single blockbuster anticoagulant (ELIQUIS), representing a mature but consolidating therapeutic area.

$26.9B marketMature→ Stable30 products15 companies

Key Trends

  • Extreme market concentration: 68% of spending driven by one FXa inhibitor product
  • Psychiatric and migraine therapies emerging as secondary growth drivers
  • High clinical trial activity (8,279 trials) signals continued pipeline development

Career Verdict

Neurology offers solid career stability with good hiring demand, but limited upside growth—best suited for professionals seeking established market positions rather than emerging-area innovation.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1ELIQUISStable
$18.3B
Bristol Myers Squibb·Launch15.0yr
$1.8B
#3BRILINTAStable
$692M
AstraZeneca·Peak10.2yr
#4NUPLAZIDStable
$596M
$530M
Johnson & Johnson·Peak15.6yr

Drug Class Breakdown

FXa Inhibitors (anticoagulant)
$18.3B(68%)

market-defining single product

Dopamine/Serotonin Antagonists (psychiatric)
$2.4B(9%)

stable mature class

P2Y12 Receptor Antagonists (antiplatelet)
$692M(3%)

niche but stable

5-HT2A Inverse Agonists (psychiatric)
$596M(2%)

specialty indication focus

CGRP Receptor Antagonists (migraine)
$931M(3%)

emerging growth segment

Immunomodulators (MS)
$747M(3%)

stable with LOE risk

Other mechanisms
$2.6B(10%)

diverse small products

Career Outlook

Stable

Neurology represents a mature, cash-generative market with limited growth tailwinds but strong hiring stability. The dominance of ELIQUIS creates a bifurcated career landscape: high-opportunity positions in emerging segments (CGRP antagonists, psychiatric therapeutics) and commoditized roles in anticoagulant franchises. Job availability is solid but growth expectations should be tempered relative to oncology or immunology.

Breaking In

Entry-level professionals should target clinical operations or commercial support roles at J&J, AstraZeneca, or Sanofi to build domain expertise in neurology disease states and competitive dynamics.

For Experienced Professionals

Experienced professionals should prioritize emerging mechanism roles (CGRP, tau-targeting programs) or pivot to medtech/neurotech (Stryker, Medtronic) to capture higher growth and salary potential than traditional pharma incumbents.

In-Demand Skills

Medical Science Liaisons (MSL) for specialist engagementClinical trial operations expertisePsychiatric/neurodegenerative disease educationRegulatory affairs (given patent cliff activity)Commercial strategy around branded/generic transitions

Best For

Medical Science LiaisonCommercial Brand Manager (anticoagulant/psychiatric franchises)Clinical Operations ManagerRegulatory Affairs SpecialistClinical Development Manager (CGRP/immunomodulator pipelines)

Hiring Landscape

$100K-$199K

Neurology shows moderate but distributed hiring across pharma and medtech employers, with 4,186 total jobs listed. Commercial functions lead (947 roles, $169K avg), followed by clinical operations (467 roles, $132K avg), indicating bias toward commercialization over R&D. Takeda leads external hiring (762 jobs) with strong representation in contract research and CRO spaces.

4,186
Open Roles
5
Companies Hiring
5
Departments

Top Hiring Companies

762Growing
434Stable
302Stable

By Department

Commercial(23%)
$169K
Clinical Operations(11%)
$132K
Engineering(8%)
$199K
IT(4%)
$100K
Manufacturing(3%)
$170K

Commercial and clinical operations roles dominate, offering stable mid-career positions; engineering roles command premium salaries ($199K), suggesting strong device/neurotech hiring pockets.

Competitive Landscape

10 companies ranked by most advanced pipeline stage

Zambon
ZambonItaly - Bresso
1 program
1
Safinamide MethanesulfonatePhase 41 trial
Active Trials
NCT03841604Completed94Est. May 2021
Clevexel Pharma
Clevexel PharmaFrance - Paris
1 program
1
CVXL-0107Phase 21 trial
Active Trials
NCT02641054Completed21Est. Jul 2017
GID Bio
GID BioCO - Louisville
1 program
1
Adipose-derived stromal vascular fraction cellsPhase 1/2
Biocorp
BiocorpFrance - Issoire
1 program
1
Adipose-derived stromal vascular fraction cellsPhase 1/21 trial
Active Trials
NCT05699161Completed10Est. Oct 2022
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
1
Human Stem CellsPhase 11 trial
Active Trials
NCT02780895Unknown8Est. Dec 2018
Pfizer
PfizerNEW YORK, NY
1 program
1
PF-06649751Phase 11 trial
Active Trials
NCT02373072Completed18Est. Mar 2016
UCB Pharma
UCB PharmaBelgium - Brussels
2 programs
Transdermal Rotigotine User Surveillance StudyN/A1 trial
LevetiracetamPHASE_21 trial
Active Trials
NCT00599339Completed2,195Est. Apr 2014
NCT00160576Completed30Est. Nov 2004
Purdue Pharma
Purdue PharmaCT - Stamford
1 program
Lee Silverman Voice TreatmentN/A1 trial
Active Trials
NCT03700684Completed36Est. Nov 2022
Supernus Pharmaceuticals
1 program
XADAGON/A1 trial
Active Trials
NCT03944785Completed164Est. Jan 2020
Labcorp
LabcorpBURLINGTON, NC
1 program
MRx0029PHASE_11 trial
Active Trials
NCT05832775Withdrawn0Est. Apr 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
ZambonSafinamide Methanesulfonate
Clevexel PharmaCVXL-0107
UCB PharmaLevetiracetam
BiocorpAdipose-derived stromal vascular fraction cells
LabcorpMRx0029
PfizerPF-06649751
Angeles TherapeuticsHuman Stem Cells
Purdue PharmaLee Silverman Voice Treatment
Supernus PharmaceuticalsXADAGO
UCB PharmaTransdermal Rotigotine User Surveillance Study

Clinical Trials (10)

Total enrollment: 2,576 patients across 10 trials

NCT03841604ZambonSafinamide Methanesulfonate

Effect of Safinamide on Parkinson's Disease Related Chronic Pain

Start: Apr 2019Est. completion: May 202194 patients
Phase 4Completed

Efficacy Phase IIa Study of CVXL-0107 in Advanced Parkinson's Disease

Start: Feb 2016Est. completion: Jul 201721 patients
Phase 2Completed

Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias

Start: Jul 2003Est. completion: Nov 200430 patients
Phase 2Completed
NCT05699161BiocorpAdipose-derived stromal vascular fraction cells

Adipose-derived Stromal Vascular Fraction Cells to Treat Parkinson

Start: Oct 2021Est. completion: Oct 202210 patients
Phase 1/2Completed

Study to Assess the Safety of MRx0029 or MRx0005 Compared to Placebo, in People With Parkinson's

Start: May 2022Est. completion: Apr 20230
Phase 1Withdrawn

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease

Start: Mar 2015Est. completion: Mar 201618 patients
Phase 1Completed

Parkinsonian Brain Repair Using Human Stem Cells

Start: May 2014Est. completion: Dec 20188 patients
Phase 1Unknown
NCT03700684Purdue PharmaLee Silverman Voice Treatment

Voice Treatment for Parkinson's Disease

Start: Sep 2018Est. completion: Nov 202236 patients
N/ACompleted

Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)

Start: Nov 2017Est. completion: Jan 2020164 patients
N/ACompleted
NCT00599339UCB PharmaTransdermal Rotigotine User Surveillance Study

Transdermal Rotigotine User Surveillance Study

Start: Jun 2006Est. completion: Apr 20142,195 patients
N/ACompleted

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.